TransMedics Group, Inc. Stock price

Equities

TMDX

US89377M1099

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 03:59:56 2024-02-23 pm EST 5-day change 1st Jan Change
83.08 USD -2.04% Intraday chart for TransMedics Group, Inc. -7.62% +5.26%
Sales 2023 * 228M Sales 2024 * 330M Capitalization 2.71B
Net income 2023 * -29M Net income 2024 * -21M EV / Sales 2023 * 12 x
Net Debt 2023 * 18.2M Net Debt 2024 * 121M EV / Sales 2024 * 8.58 x
P/E ratio 2023 *
-92.7 x
P/E ratio 2024 *
-122 x
Employees 212
Yield 2023 *
-
Yield 2024 *
-
Free-Float 96.55%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.04%
1 week-7.62%
Current month-3.14%
1 month-2.18%
3 months+20.49%
6 months+26.76%
Current year+5.26%
More quotes
1 week
83.00
Extreme 83
90.92
1 month
82.84
Extreme 82.84
90.92
Current year
73.19
Extreme 73.19
90.92
1 year
36.42
Extreme 36.4201
99.63
3 years
10.00
Extreme 10
99.63
5 years
10.00
Extreme 10
99.63
10 years
10.00
Extreme 10
99.63
More quotes
Managers TitleAgeSince
Founder 55 98-07-31
Director of Finance/CFO 56 15-02-28
Chief Tech/Sci/R&D Officer - 06-02-28
Members of the board TitleAgeSince
Chairman 79 10-12-31
Director/Board Member 67 02-12-31
Director/Board Member 68 20-12-31
More insiders
Date Price Change Volume
24-02-23 83.14 -1.97% 636,793
24-02-22 84.81 -2.51% 784,317
24-02-21 86.99 -1.83% 439,905
24-02-20 88.61 -1.47% 497,378
24-02-16 89.93 +0.53% 473,876

Delayed Quote Nasdaq, February 23, 2024 at 03:59 pm EST

More quotes
TransMedics Group, Inc. is a commercial-stage medical technology company. It is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. It has designed and developed an organ care system (OCS), a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It designed its OCS technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state. It has developed OCS products, one each for lung, heart and liver transplantation. Its products include OCS Heart, OCS Lung and OCS Liver. Its OCS product consists of three components customized for each organ, which include the OCS Console, OCS Perfusion Set and OCS Solutions. The Company is also a provider of air logistics dedicated to organ transplantation in the United States.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
83.14 USD
Average target price
90 USD
Spread / Average Target
+8.25%
Consensus
  1. Stock
  2. Equities
  3. Stock TransMedics Group, Inc. - Nasdaq
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer